Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric Biosciences' robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more.
• Powerful IP portfolio - 14 Patents filed
• Multi-billion-dollar opportunities with large patient populations in mind and body
• Psybrary contains 1M+ molecules encompassing Gen2 and Gen3, including nonhallucinogenics
• PsyAI allows us allows us to target indications and accelerate pathway to an IND
• Experienced Team from Discovery through Phase 3 Clinicals
• Strong Financial Position:$20M in cash and NASDAQ traded